CLDX Stock Forecast 2025-2026
Distance to CLDX Price Targets
CLDX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Celldex (CLDX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CLDX and similar high-potential opportunities.
Latest CLDX Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, CLDX has a bullish consensus with a median price target of $63.50 (ranging from $36.00 to $90.00). Currently trading at $18.30, the median forecast implies a 247.0% upside. This outlook is supported by 12 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yatin Suneja at Guggenheim, projecting a 391.8% upside. Conversely, the most conservative target is provided by Richard Law at Goldman Sachs, suggesting a 96.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLDX Analyst Ratings
CLDX Price Target Range
Latest CLDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2025 | Morgan Stanley | Judah Frommer | Overweight | Initiates | $46.00 |
| Mar 3, 2025 | Goldman Sachs | Richard Law | Neutral | Maintains | $36.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Feb 13, 2025 | UBS | Trung Huynh | Buy | Initiates | $44.00 |
| Jan 29, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Jan 2, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Oct 28, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Oct 7, 2024 | Citigroup | David Lebowitz | Buy | Initiates | $70.00 |
| Sep 30, 2024 | Goldman Sachs | Richard Law | Neutral | Initiates | $45.00 |
| Sep 27, 2024 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $0.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $80.00 |
| Sep 25, 2024 | Wolfe Research | Andy Chen | Outperform | Reiterates | $51.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Sep 18, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $67.00 |
Celldex Therapeutics Inc. (CLDX) Competitors
The following stocks are similar to Celldex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Celldex Therapeutics Inc. (CLDX) Financial Data
Celldex Therapeutics Inc. has a market capitalization of $1.21B with a P/E ratio of -7.5x. The company generates $7.02M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -71.6% quarter-over-quarter, while maintaining an operating margin of -4,768.3% and return on equity of -26.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Celldex Therapeutics Inc. (CLDX) Business Model
About Celldex Therapeutics Inc.
Develops innovative immunotherapy treatments for cancer.
Celldex Therapeutics operates as a clinical-stage biotechnology company focusing on the development of targeted therapeutic candidates. It generates revenue primarily through partnerships and collaborations in research and development, seeking to create biologic therapies such as vaccines and monoclonal antibodies that address unmet medical needs.
The company is positioned in a rapidly evolving biotechnology sector and aims to contribute to personalized medicine. Its ongoing research and collaborations highlight its commitment to advancing immunotherapy, which is crucial for treating complex medical conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
186
CEO
Mr. Anthony S. Marucci M.B.A.
Country
United States
IPO Year
1990
Website
www.celldex.comCelldex Therapeutics Inc. (CLDX) Latest News & Analysis
CDX-622 is being studied in a Phase 1 trial for its ability to inhibit SCF and TSLP-dependent inflammatory signatures in human skin, currently involving healthy volunteers.
CDX-622's potential to inhibit inflammatory responses could position it as a valuable treatment, influencing market perceptions and investment in biotech sectors focused on dermatological therapies.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) will participate in fireside chats at two upcoming conferences, as announced on March 4, 2025.
Management participation in conferences can signal potential developments or insights into Celldex's strategy, impacting stock performance and investor sentiment.
82% of Chronic Spontaneous Urticaria (CSU) patients and 60% of Chronic Inducible Urticaria (CIndU) patients reported improved quality of life after treatment, indicating effective outcomes.
Positive patient outcomes in CSU and CIndU indicate strong product efficacy, potentially driving higher sales and market share for related pharmaceutical companies.
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
1 month agoCelldex Therapeutics, Inc. (NASDAQ:CLDX) reported its financial results for Q4 and the full year of 2024 on February 27, 2025, along with a corporate update.
Celldex Therapeutics' financial results and corporate update can impact stock performance, signaling potential growth or risks that may influence investor sentiment and decisions.
Celldex Therapeutics (CLDX) reported a quarterly loss of $0.71 per share, better than the expected loss of $0.75, but worse than the $0.57 loss from the same quarter last year.
Celldex's smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Celldex Therapeutics has begun a Phase 2 trial for barzolvolimab in treating atopic dermatitis, a common skin disease affecting up to 20% of the U.S. population. The study is currently enrolling patients.
Celldex's Phase 2 study of barzolvolimab for atopic dermatitis could drive significant revenue potential, given the high prevalence of the condition and its market demand for effective treatments.
Frequently Asked Questions About CLDX Stock
What is Celldex Therapeutics Inc.'s (CLDX) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, Celldex Therapeutics Inc. (CLDX) has a median price target of $63.50. The highest price target is $90.00 and the lowest is $36.00.
Is CLDX stock a good investment in 2025?
According to current analyst ratings, CLDX has 12 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLDX stock?
Wall Street analysts predict CLDX stock could reach $63.50 in the next 12 months. This represents a 247.0% increase from the current price of $18.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Celldex Therapeutics Inc.'s business model?
Celldex Therapeutics operates as a clinical-stage biotechnology company focusing on the development of targeted therapeutic candidates. It generates revenue primarily through partnerships and collaborations in research and development, seeking to create biologic therapies such as vaccines and monoclonal antibodies that address unmet medical needs.
What is the highest forecasted price for CLDX Celldex Therapeutics Inc.?
The highest price target for CLDX is $90.00 from Yatin Suneja at Guggenheim, which represents a 391.8% increase from the current price of $18.30.
What is the lowest forecasted price for CLDX Celldex Therapeutics Inc.?
The lowest price target for CLDX is $36.00 from Richard Law at Goldman Sachs, which represents a 96.7% increase from the current price of $18.30.
What is the overall CLDX consensus from analysts for Celldex Therapeutics Inc.?
The overall analyst consensus for CLDX is bullish. Out of 15 Wall Street analysts, 12 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $63.50.
How accurate are CLDX stock price projections?
Stock price projections, including those for Celldex Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.